Investment Thesis
OS Therapies faces imminent financial distress with negative stockholders equity of -$10.8M and liabilities exceeding assets by $9.8M, indicating technical insolvency. The company has critical liquidity crisis with current ratio of 0.05x and only $917.6K cash against -$5.0M free cash flow, providing less than two months of runway without financing. With no reported revenue and sustained operating losses, the company requires immediate capital infusion for survival.
Strengths
- YoY improvement in diluted EPS loss (23.4%) suggests cost management progress
- Minimal asset base consistent with early-stage biotech R&D focus
- Company remains operationally active despite severe financial constraints
Risks
- Negative stockholders equity of -$10.8M indicates technical insolvency on accounting basis
- Critical liquidity crisis: current and quick ratios of 0.05x signal inability to meet near-term obligations
- Estimated cash runway under two months at current burn rate creates existential funding risk
- Liabilities of $17.1M exceed total assets of $7.3M by $9.8M
- Negative operating cash flow of -$4.6M and negative free cash flow of -$5.0M unsustainable
- Pre-revenue or minimal revenue status with no clear path to profitability
- Zero insider Form 4 activity in last 90 days suggests potential loss of confidence
Key Metrics to Watch
- Cash position and months of runway remaining before depletion
- Announcement of financing or capital raise and dilution impact
- Operating burn rate trajectory and cost reduction initiatives
- Revenue recognition timeline and commercial milestone achievement
- Balance sheet restructuring or debt forbearance agreements
Financial Metrics
Revenue
N/A
Net Income
-10.4M
EPS (Diluted)
$-0.27
Free Cash Flow
-5.0M
Total Assets
7.3M
Cash
917.6K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-142.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.05x
Quick Ratio
0.05x
Debt/Equity
N/A
Debt/Assets
233.6%
Interest Coverage
-12.27x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:59:42.393752 |
Data as of: 2026-03-31 |
Powered by Claude AI